Pulmonary Toxicity After G-CSF Combined Chemotherapy for Non-Hodgkin's Lymphoma
Author Information
Author(s): N Yokose, K Ogata, H Tamura, E An, K Nakamura, K Kamikubo, S Kudoh, K Dan, T Nomura
Primary Institution: Nippon Medical School, Tokyo, Japan
Hypothesis
Is G-CSF associated with the development of pulmonary toxicity in patients receiving chemotherapy for non-Hodgkin's lymphoma?
Conclusion
G-CSF is associated with a higher incidence of pulmonary toxicity in patients receiving CHOP therapy for non-Hodgkin's lymphoma.
Supporting Evidence
- 6 out of 52 subjects (11.5%) developed pulmonary toxicity.
- The mean peak leucocyte count was associated with the development of toxicity.
- Early application of high-dose corticosteroid led to cure in all cases.
Takeaway
Some patients who received a specific cancer treatment developed lung problems, and it seems that a medicine called G-CSF made this worse.
Methodology
The study analyzed 52 patients with non-Hodgkin's lymphoma treated with CHOP therapy and G-CSF, evaluating the incidence of pulmonary toxicity and associated characteristics.
Limitations
The study only included patients treated at one institution and may not be generalizable to all populations.
Participant Demographics
Patients were newly diagnosed with non-Hodgkin's lymphoma, with a mix of genders and ages ranging from 24 to 67 years.
Statistical Information
P-Value
0.020
Statistical Significance
p=0.020
Want to read the original?
Access the complete publication on the publisher's website